Abstract
Atypical adenomatous hyperplasia (AAH) is a putative precursor of bronchioloalveolar carcinoma (BAC) and adenocarcinoma of the lung, developing from terminal respiratory unit cells. AAH and BAC lesions typically present as ground-glass opacities at spiral chest computed tomography. Epidermal growth factor receptor polysomy/mutations, conferring higher sensitivity to Gefitinib, are frequent in BAC but less common in AAH. We describe an interesting case of disseminated AAH showing a sustained remission under Gefitinib therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 266-267 |
| Number of pages | 2 |
| Journal | Journal of Thoracic Oncology |
| Volume | 4 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2009 |
Keywords
- AAH
- BAC
- CT screening
- FISH
- Gefitinib
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Medicine(all)
Fingerprint Dive into the research topics of 'Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib'. Together they form a unique fingerprint.
Cite this
Pastorino, U., Calabrò, E., Tamborini, E., Marchianò, A., Orsenigo, M., Fabbri, A., Sozzi, G., Novello, S., & De Marinis, F. (2009). Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib. Journal of Thoracic Oncology, 4(2), 266-267. https://doi.org/10.1097/JTO.0b013e3181952930